22:43 , Sep 13, 2018 |  BC Week In Review  |  Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
23:38 , Sep 6, 2018 |  BC Extra  |  Company News

Zealand brings in $205M for pipeline via Royalty Pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) Mouse studies identified a peptide-based GLP-2R activator that could help treat IBD. Chemical synthesis and testing in a cell-based activity assay of GLP-2-based stapled peptides yielded a peptide that activated...
21:03 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Zealand's glepaglutide meets in Phase II for SBS

Zealand Pharma A/S (CSE:ZEAL) reported data from a Phase II trial in 16 patients with short bowel syndrome (SBS) showing that once-daily subcutaneous glepaglutide (ZP1848) met the primary endpoint of reducing fecal wet weight output...
19:02 , Jul 7, 2017 |  BC Extra  |  Financial News

Zealand planning NASDAQ listing

Metabolic company Zealand Pharma A/S (CSE:ZEAL) filed to raise up to $86.3 million via a listing of ADSs on NASDAQ underwritten by Morgan Stanley and Goldman Sachs. Zealand's partner Sanofi (Euronext:SAN; NYSE:SNY) markets the company's...
20:13 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

Glepaglutide: Completed Ph II enrollment

Zealand completed enrollment of about 18 patients in a double-blind, crossover, Danish Phase II trial evaluating 3 dose levels of subcutaneous glepaglutide given by an injectable pen device in 3-week periods. Zealand Pharma A/S (CSE:ZEAL),...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Elsiglutide: Phase IIb data

Top-line data from a double-blind, European Phase IIb trial in 497 colorectal cancer patients receiving 5-fluorouracil (5-FU) showed that once-daily subcutaneous elsiglutide missed the primary endpoint of reducing the proportion of patients experiencing grade >=2...
01:45 , May 5, 2016 |  BC Extra  |  Clinical News

Helsinn's elsiglutide misses in Phase IIb trial

Helsinn Healthcare S.A. (Lugano, Switzerland) said elsiglutide ( ZP1846 ) missed the primary endpoint in a Phase IIb study to prevent chemotherapy-induced diarrhea in colorectal cancer patients. The company said elsiglutide "had a positive numerical...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

ZP1848: Phase II started

Zealand began a double-blind, crossover Phase II trial to evaluate 3 dose levels of ZP1848 given by an injectable pen device in 18 patients. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark   Product: ZP1848   Business:...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Elsiglutide: Phase IIb started

Helsinn began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 10, 20 and 40 mg subcutaneous elsiglutide once daily for 4 days in about 600 patients with colorectal cancer receiving 5-fluorouracil (5-FU)-based chemotherapy. A...